fh-mcva2tcr
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2019 (NCT03747484)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03747484 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2019 | Affini-T Therapeutics, Inc., National Cancer Institute (NCI), University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affini-T Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1